Skip to main content
Sean Pittock, MD, Neurology, Rochester, MN

Sean J Pittock MD

Hospital/Neurohospitalist


Professor, Neurology, Mayo Medical School

Join to view full profile
  • 200 1st St SwRochester, MN 55905

  • Phone+1 507-284-2511

Dr. Pittock is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2003
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1999 - 2002
  • University College of Dublin National Univ SOM
    University College of Dublin National Univ SOMClass of 1993

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2001 - 2027
  • OK State Medical License
    OK State Medical License 2017 - 2024
  • CT State Medical License
    CT State Medical License 2017 - 2023
  • TN State Medical License
    TN State Medical License 2016 - 2023
  • IL State Medical License
    IL State Medical License 2014 - 2020
  • Neurology
    American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2016
  • CMS Meaningful Use Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2016
  • CMS Meaningful Use Stage 1 Certification Centricity Patient Online, GE Healthcare, 2014-2016

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients with Myelin Oligodendrocyte Glycoprotein IgG–Associated Disorders  
    Amy Kunchok, Brian G Weinshenker, Eoin P Flanagan, Sean J Pittock, JAMA Neurology
  • Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis  
    Divyanshu Dubey, John Cheville, Thomas Kryzer, Chadwick Hales, Jorge Kattah, Eoin P Flanagan, Anastasia Zekeridou, Jenny J Linnoila, Andrew Mckeon, Sean J Pittock, JAMA Neurology
  • Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events  
    Amy Kunchok, Allen J Aksamit, Sean J Pittock, Brian G Weinshenker, Andrew Mckeon, JAMA Neurology

Authored Content

  • Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients with Myelin Oligodendrocyte Glycoprotein IgG–Associated DisordersAugust 2020
  • Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 EncephalitisAugust 2020
  • Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 EncephalitisAugust 2020

Press Mentions

  • Long-Term Control of Neuromyelitis Optica Spectrum Disorder with Ravulizumab
    Long-Term Control of Neuromyelitis Optica Spectrum Disorder with RavulizumabOctober 3rd, 2025
  • 48 36 (75.0%) 12 (25.0%)
    48 36 (75.0%) 12 (25.0%)August 19th, 2022
  • Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
    Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum DisorderMay 5th, 2022

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: